Recent

% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Hi biotech_invest

    Thanks for dropping by and setting the record straight with i hurt's personal experience and his opinions on CLSN which are clearly pessimistic in nature about CLSN future which seems to be on a turn around, better, and brighter.

    I checked out your website and you have an interesting list of "scam stocks"...
    On that short list of "scam stocks" you list XOMA which I was surprised.
    I had invested in them years ago, they had a product approved by the FDA and then I lost touch.
    Prime candidate I would expect to see listed as a scam would be something like CTIC...

    Regards,
    Ron

  • " those who forget the past are condemned to repeat it..." and not a single analyst, institutional or retail, puts much weight to such trite phrases. BTW, how short are you?

  • already here...

    Analysts at Griffin Securities set a $7.00 target price on shares of Celsion (NASDAQ:CLSN) stock in a research report issued to clients and investors on Thursday. The firm currently has a a “buy” rating on the stock. Griffin Securities’ price objective suggests a potential upside of 122.22% from the company’s current price.
    Celsion (NASDAQ:CLSN) opened at 3.15 on Thursday. Celsion has a 52-week low of $2.15 and a 52-week high of $3.73. The stock’s 50-day moving average is $2. and its 200-day moving average is $2.. The company’s market cap is $62.95 million.
    Celsion (NASDAQ:CLSN) last released its earnings data on Thursday, March 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.04. On average, analysts predict that Celsion will post $-1.29 earnings per share for the current fiscal year.
    Separately, analysts at Cantor Fitzgerald set a $7.00 price target on shares of Celsion and gave the company a “buy” rating in a research note on Wednesday.
    Celsion Corporation is an oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer. As of December 31, 2011, the Company’s product ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer (NASDAQ:CLSN), a Phase II clinical trial for colorectal liver metastasis (CRLM) and a Phase II clinical trial for recurrent chest wall breast cancer.

  • Separately, analysts at Cantor Fitzgerald set a $7.00 price target on shares of Celsion and gave the company a “buy” rating in a research note on Wednesday.

  • Analysts at Griffin Securities set a $7.00 target price on shares of Celsion (NASDAQ:CLSN) stock in a research report issued to clients and investors on Thursday. The firm currently has a a “buy” rating on the stock. Griffin Securities’ price objective suggests a potential upside of 122.22% from the company’s current price.
    Celsion (NASDAQ:CLSN) opened at 3.15 on Thursday. Celsion has a 52-week low of $2.15 and a 52-week high of $3.73. The stock’s 50-day moving average is $2. and its 200-day moving average is $2.. The company’s market cap is $62.95 million.
    Celsion (NASDAQ:CLSN) last released its earnings data on Thursday, March 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.04. On average, analysts predict that Celsion will post $-1.29 earnings per share for the current fiscal year.

    Sentiment: Buy

  • Reply to

    Celsion will see revenue in Q2.

    by edvoks Apr 16, 2015 12:46 PM

    This is truly great news. One thing concerned me in the past is future dilution of CSLN shares. The revenue stream will provide some relief.

  • will not agree with your pessimistic conclusions about CLSN future.
    I also become skeptical about CLSN trial results and even sold all shares before release (read below from my webpage biotechinvestDOTnet:

    12.14.12 by BiotechInvest
    I have changed my opinion for CLSN to Neutral. In January company will release data from clinical trial and CLSN pps will jump or crashed badly ($1-2 is the best scenario).
    Why I change my minds?
    Just asked myself several questions:
    1) Will CLSN technology prolong cancer patients survival 5 times from control group? Answer is NO
    2) If treated group live 20-30% more will FDA approve this treatment? Answer is NO
    3) If it's +50% Overall Survival (OS) and FDA approve treatment will doctors sent patients for ThermoDox (50% OS or DCTH treatment (5 times increase Overall survival time)? Answer is NO

    01.30.2013 by BiotechInvest
    CLSN is still keeping silence about phase III results. They were promised then in January. It's very bad sign. It seems like that statisticians can not get any big difference between placebo treatment group (RFA only) and ThermoDox+RFA group. If it's less than 20-25% CLSN is doomed. DNDN won when got 22% but it was SPA with FDA that results should be at 20%.
    I even think about to short CLSN right now because if this silence continues to February investors will panic and sell CLSN.

    I was not persuaded that CLSN insiders never sell shares and after China company pay $5M for Thermodox licensing.
    But now I think that the probability of success is higher. The reason is simple: CLSN management admitted their mistakes with treatment regiment (need 45 min of heating) and treatment conditions are optimal now. May be longer heating of cancer lesions is needed for for more effective Dox release from liposomes? Any way I bought 10k CLSN and will keep them before they release data.

    Sentiment: Strong Buy

  • Now to China, our application for study approval for the China FDA and the CFDA is nearing final review. This review is taken longer than we anticipated, but we have been in the queue with every other Phase III study that’s been submitted. We understand now with the study is currently being reviewed, we expect approval in the very near-term, CFDA officials have communicated to us through Dr. Borys and me personally that they have committed to working with us to initiate the OPTIMA study as quickly as possible.

    Supporting their interest we talked about this last call is some very interesting data from over 200 patients who are enrolled in the HEAT study from 200 patients from China and Hong Kong. Of the 150 for our Chinese patient cohort with a single lesion and that’s what we are focused on. Over 70% of these patients receive the treatment from standardized RFA that’s over 45 minutes or greater, 70% are Chinese patients.

  • Reply to

    Before you invest in Thermodox

    by truth_r_consequences Apr 17, 2015 12:37 PM

    It is basically a lifetime license of the patent, plus they get 7yr. Orphan Drug exclusivity if/when they are approved and Orphan Drug exclusivity is in place whether or not there is a viable patent.

  • Reply to

    Before you invest in Thermodox

    by truth_r_consequences Apr 17, 2015 12:37 PM

    Good catch edvoks !!!

    Truth sounds like a former long term investor, sounds knowledgeable about the company and Tdox.
    I do agree that Tdox should have been wrapped up and approved years ago.
    Not sure why the OR part was left out of his warning.
    Big difference between 2019 and 2026.

  • Reply to

    Before you invest in Thermodox

    by truth_r_consequences Apr 17, 2015 12:37 PM

    You double-check the fine print, they have till 2019 OR till the end of their patent runway, and that patent runway was extended till 2026.

    until the full end of the term or terms
    for which a patent is issued by the U.S. Patent and Trademark Office in respect
    of the PATENT RIGHTS, whichever is longer

    LICENSOR hereby grants to LICENSEE and LICENSEE hereby accepts
    from LICENSOR, upon the terms and conditions herein specified, an exclusive,
    sublicensable license under the HEAT TRIGGERED DELIVERY TECHNOLOGY and the
    PATENT RIGHTS to practice the INVENTIONS and to, directly or indirectly, make,
    import, export, use, lease, sell or otherwise dispose of LICENSED PRODUCTS for a
    period of (i) twenty (20) years or (ii) until the full end of the term or terms
    for which a patent is issued by the U.S. Patent and Trademark Office in respect
    of the PATENT RIGHTS, whichever is longer

  • Double check the fine print. Duke University owns the rights. CLSN has only licensed it and its up in around 3 years. Not much time for a drug that's still in clinical trial level II. Even if fast track is given by the FDA, there will be scant little time prior to CLSN renegotiating rights with DUKE and the sad part is, the more successful the outcome appears to be - the more YOU, the shareholders are going to have to give up out of future profits. Truthfully, the entire business plan vis a vis thermodox was designed to succeed 5 years ago. As another poster said, they initially went after the Liver Cancer sufferers amidst great hype and hoopla, questionable and misleading statements only to fail miserably without much of an explanation. Im sure were it not for managements repeated symbol changes, name changes, reverse splits and back door "PIPE" deals, this company would not be in business today. There are many company's that do what CLSN does (search for cures for cancer and fail for decades) but trust me, if they weren't biotechs, the financial plug would have been pulled long, long ago. Can you imagine any other type of company that could have failed so miserably and yet stayed in business for decades, year after year luring in unsuspecting and hopeful dolts. Read; lambs to the slaughter. I say to you now: BUYER BEWARE; CAVEAT EMPTOR!

  • Reply to

    FDA Approval coming soon!

    by disintegration001 Apr 15, 2015 2:49 PM

    BIIB also a patient died... but unknown what really caused. The many patients treat with same Clinical trial medication improved 99%, but one passed away.. it doesn't meant the product is bad. Today Market is selling off and CLSN is holding pretty well.. Long term investors holding their shares. I am new on this board. Bought yesterday at 3.45.. will buy more. and wait for FDA...

    Sentiment: Strong Buy

  • kccjfc@prodigy.net kccjfc Apr 17, 2015 9:26 AM Flag

    See if there's a pr. Presentation made over 6 hours ago in Utrecht.

  • tw.smith@sbcglobal.net tw.smith Apr 16, 2015 10:10 PM Flag

    One thing Is certain: it is futile to attempt to present facts or red flags to those who are blinded by biotech pipe dreams. They are dilusional and have no interest in knowing facts because facts take them out of their cozy little dreams of getting rich off one of these shady companies. 95% of biotechs are at best well intended but doomed from the start and at worst are total scams. Either way, there is a never ending pool of suckers who will fumble over their money and watch it disappear month after month and year after year. Don't waste your breath trying to talk them out if it. Sell to them instead. Shorting garbage like this is where the REAL $ is at.

  • Reply to

    FDA Approval coming soon!

    by disintegration001 Apr 15, 2015 2:49 PM

    LIAR - you should know that in cancer terms a complete response means that disappearance of all signs of cancer in response to treatment. This does not always mean the cancer has been cured. Also called complete remission. The subject in this study who had "a complete response" is very much alive. Do not lie as people's lives are at stake. I have 35 years in medicine so there.

  • $1.90s or $3.00?
    answer was $3.00+

    now the question is once again
    $1.90s or $3.00 again?

    clsn needs cash to make anything come to fruition
    fundraisers = D I L U T I O N

  • Reply to

    FDA Approval coming soon!

    by disintegration001 Apr 15, 2015 2:49 PM

    It doesn't mean is from CLDN product. Take a look on BIIB where a MS patient died from chemical found on one BIIB experimental drug for MS. Get lost, basher

    Sentiment: Strong Buy

  • The Company expects to have ThermoDox® available for the EAP in the second quarter of 2015.

  • And 5 of 12 is just for COMPLETE RESPONSE, the others have seen partial response or tumor control.

Must Watch
CLSN
2.35-0.01(-0.42%)Jul 2 4:00 PMEDT